Efficacy of measles and rubella vaccination one year after the nationwide campaign in Shiraz, Iran.
BACKGROUND
The World Health Organization target for measles elimination in the Eastern Mediterranean Region was established in 2010. In Iran, the national measles-rubella campaign, targeting individuals aged 5-25 years, was initiated in December 2003.


METHODS
To evaluate the impact of the campaign after one year, 909 serum samples were collected in Shiraz, southern Iran, from a population aged 6-26 years, divided into five groups according to age. IgG antibodies were tested using ELISA for the measles and rubella antibodies, and the plaque reduction neutralization test (PRNT; measles) was used for samples with equivocal results.


RESULTS
Measles protective immunity reached 80.6%, 72.7%, 84.9%, and 87.5% and rubella immunity reached 91.0%, 99.6%, 99.6%, and 97.0% for the age groups 6-10, 11-15, 16-20, and 20-26 years, respectively. Seropositivity to the rubella virus in this population was high, especially in women of childbearing age (98.9%), thereby preventing congenital rubella infections. However for measles, it was significantly lower than the rate required to achieve >or=95% coverage for elimination.


CONCLUSIONS
These data indicate that an increase in immunization coverage by supplementary administration of a second dose of measles vaccine is needed to interrupt the endemic transmission of the measles virus.
Pourabbas
Bahman
B
Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. bpourabbas@yahoo.com
Ziyaeyan
Mazyar
M
Alborzi
Abdolvahab
A
Mardaneh
Jalal
J
D000293:Adolescent; D000328:Adult; D002648:Child; D006801:Humans; D007109:Immunity; D007492:Iran / Q000453:epidemiology; D032541:Mass Vaccination; D008457:Measles / Q000276:immunology / Q000517:prevention & control; D008458:Measles Vaccine / Q000276:immunology*; D015995:Prevalence; D012409:Rubella / Q000276:immunology / Q000517:prevention & control; D012411:Rubella Vaccine / Q000276:immunology*; D016036:Seroepidemiologic Studies
D008458:Measles Vaccine; D012411:Rubella Vaccine